Peptide counter-ions: TFA vs acetate vs hydrochloride, and why the salt form changes your results

A vial of synthetic peptide is not pure peptide, and the single largest non-peptide component is often the counter-ion. Any peptide with lysine, arginine or histidine residues, or a free N-terminal amine, carries positive charges in the solid state, and something has to balance them. What that something is was usually decided by the purification chemistry rather than by anyone’s deliberate choice, and it changes the mass you weigh out, the infrared spectrum you record and sometimes the biological result you report.

This guide covers why trifluoroacetate is the default, how acetate, chloride and other salts compare, the published evidence that counter-ions change assay outcomes, the methods for exchanging and measuring them, and how the salt form should read on a certificate of analysis.

Why peptides come as salts at all

Peptide side chains are ionisable. Aspartate, glutamate and the C-terminal carboxyl are anionic; lysine, arginine, histidine and the N-terminal amine are cationic [1]. A review of peptide counter-ions notes how environment-dependent this is: the pKa values of lysine in pure water at 25 degrees Celsius are 11.08 and 9.05 for the amino groups and 1.76 for the carboxyl group, but in 70% ethanol they shift to 9.64, 8.48 and 2.19 [1]. A peptide isolated from an acidic mobile phase is therefore protonated at its basic sites, and the acid’s anion comes with it.

The counter-ion can be an anion such as trifluoroacetate, acetate or chloride, or a cation such as sodium, potassium or calcium for acidic peptides [1]. EMA’s requirement is stated at the structure level: “the counter ion needs to be indicated, if relevant, and whether it is present in a stoichiometric or non-stoichiometric ratio”, and “in the event that there is no counter ion, the free base should be indicated” [2].

Why TFA is the default, and why it stays

Two independent steps in the standard workflow use trifluoroacetic acid.

First, cleavage. In Fmoc chemistry the peptide is released from the resin and the side-chain protecting groups are removed in a single acidolytic step with a TFA cocktail containing scavengers, which trap the reactive carbocations liberated from groups such as tert-butyl [10] [16]. Exposure is not brief: removing the Pbf group from arginine is usually complete within one to two hours, and peptides containing several arginine residues need extended cleavage times [14]. The Fmoc cycles themselves are TFA-free, which is one reason the strategy automated well, but the final step is not [14].

Second, purification. Reversed-phase chromatography uses an acidic ion-pairing additive, and TFA is the usual choice: it pairs with the positively charged basic residues and improves peak shape [15], and because it is volatile it can be removed by lyophilization without a desalting step [1]. The consequence is direct: Fmoc solid-phase synthesis followed by reversed-phase purification “lead to peptides as TFA salts” [1].

Trifluoroacetate then appears in two distinct forms, which matters for how hard it is to get rid of: it “may occur in two forms, either directly bonded with basic residues of peptides or adsorbed in lyophilizate as a contaminant” [1]. The bound fraction is tenacious. One evaluation describes the trifluoroacetate on the dicationic octapeptide lanreotide as a “tightly bound counter-ion” requiring deliberate exchange [7].

There is also pressure on TFA from the process side. The 2024 ACS Green Chemistry Institute Pharmaceutical Roundtable analysis lists “highly corrosive trifluoroacetic acid” among the limitations of current peptide synthesis and states that “moving forward, alternatives to TFA are recommended from a safety/sustainability standpoint” [10].

TFA vs acetate vs hydrochloride

	Trifluoroacetate	Acetate	Chloride
Parent acid	Trifluoroacetic acid	Acetic acid	Hydrochloric acid
Molecular weight of the acid	114.02 g/mol (C2HF3O2) [11]	60.05 g/mol (C2H4O2) [12]	36.46 g/mol (HCl) [13]
pKa at 25 degrees Celsius	0.52 [1]	4.76 [1]	About minus 7 [1]
Where it comes from	Cleavage cocktail and RP-HPLC additive [1] [16]	Deliberate exchange, or acetic acid as modifier; historically from countercurrent distribution [1]	Lyophilization from dilute HCl, or ion exchange [1]
Status in approved products	Some marketed peptides are trifluoroacetates [1]	Most peptide drugs and peptide-based therapeutics are acetates [1]	Rarely found among marketed peptides [1]
Removable by lyophilization	Yes, volatile [1]	Yes, volatile [1]	Yes, volatile [1]
Known assay interference	Strong IR band overlapping amide I; suppresses electrospray MS signal [1] [8]	Determined by ion chromatography or dedicated HPLC methods [1]	Not detectable by 1H NMR, needs IC [1]

EMA’s position is that “for synthetic peptides, usually acetate is used as counter ion, however, other counter-ions are also possible (e.g. trifluoroacetate or chloride)” [2]. The counter-ion review gives two reasons why acetate dominates approved products. One is trifluoroacetate’s toxicity profile. The other is historical: acetate counter-ions in early peptide drugs “were an outcome of countercurrent distribution (CCD) implementation as a last stage of purification process”, the multistage liquid-liquid extraction technique that preceded high-resolution chromatography [1]. Exchange to acetate also runs under distinctly milder conditions than exchange with hydrochloric acid at pH below 1, so it theoretically carries less risk of degradation [1].

Chloride is not automatically worse. The review cites a reported case of superior stability for a peptide hydrochloride salt against both trifluoroacetate and acetate in stability studies, and a patent comparison in which an octreotide chloride liquid-crystalline formulation released the peptide about four times more slowly than the acetate formulation and showed only a slight drop in peptide concentration after four weeks at 40 degrees Celsius, where the acetate formulation fell markedly [1].

What the counter-ion does to your results

Trifluoroacetate is biologically active

This is the finding that should change laboratory practice. Cornish and colleagues reported that trifluoroacetate at 10^-8 to 10^-7 M reduced cell numbers and thymidine incorporation in fetal rat osteoblast cultures after 24 hours, with similar effects in articular chondrocyte cultures and neonatal mouse calvariae, “indicating that the effect is not specific to one cell type or to one species of origin” [3]. Comparing salts directly, “cell proliferation was consistently less with the TFA salts” of amylin, amylin-(1-8) and calcitonin than with the hydrochloride salts, “resulting in failure to detect a proliferative effect or wrongly attributing an antiproliferative effect” [3]. Their conclusion generalises the problem: the finding “is likely to be relevant to all studies of purified peptides in concentrations above 10^-9 M in whatever cell or tissue type”, and such peptides “should be converted to a hydrochloride or biologically equivalent salt before assessment of their biological effects is undertaken” [3].

It has a receptor action

Trifluoroacetate is also a direct pharmacological agent at one well-studied channel. Using two-electrode voltage clamp on receptors expressed in Xenopus oocytes, sodium trifluoroacetate at 100 micromolar to 3 millimolar enhanced currents elicited by low concentrations of glycine at alpha-1 homomeric and alpha-1 beta heteromeric glycine receptors, with no effect when co-applied with a maximally effective glycine concentration, and no effect at alpha-1 beta-2 gamma-2S GABA-A or 5-HT3A receptors at any agonist concentration tested [4]. The authors describe trifluoroacetate as “an allosteric modulator at the glycine receptor with greater specificity than other known modulators” and note that its presence in HPLC-purified peptides is “potentially an important source of experimental variability or error that requires control” [4]. The evidence level here is heterologous expression in oocytes, not a mammalian in vivo study.

It shifts conformation

Counter-ions change secondary structure, which changes activity. In a study summarised by the counter-ion review, chloride was the least efficient of chloride, bicarbonate, sulfate and trifluoroacetate at inducing helical structure in the antimicrobial peptide LL-37 [1]. For the bacteriocin pediocin PA-1, the same review reports a slight increase in helical content with trifluoroacetate compared with chloride; the primary authors proposed replacing TFA with HCl throughout the hydrophobic purification steps, found that the change did not affect purification yield or the amount of peptide purified, and reported that the TFA-induced structural modifications did not significantly affect antimicrobial activity [5] [1]. For amyloid-beta, the review reports that the aggregation pathway itself differed: an alpha-helical intermediate followed by beta-structures and fibrils was observed only with the trifluoroacetate counter-ion, while the chloride form moved from an unordered structure to fibrils directly through a beta-sheet conformation [1].

It can change an in vivo model

A controlled comparison in an immunisation model found a timing effect. Using the MOG(35-55) peptide to induce experimental autoimmune encephalomyelitis in mice, the authors compared the same peptide preparation as trifluoroacetate and as acetate. Disease incidence and severity were similar, but “the average day of disease onset occurred approximately 5 days earlier with the use of MOG-B-containing trifluoroacetate” [6]. The same study makes a broader point that applies to every peptide experiment: the peptide fraction of commercial material “can vary from less than 50% to over 90%, with the remainder of mass primarily comprised of the counter ion used for peptide purification”, and two preparations of similar purity but different peptide fraction produced significantly different clinical scores [6]. Their conclusion is worth quoting in full: “a knowledge of peptide fraction is as critical as knowledge of peptide purity when using peptides from different sources” [6].

It breaks two common analyses

Infrared spectroscopy is the first casualty. Trifluoroacetate “has a strong infrared (IR) absorption band at 1673 cm-1, significantly overlapping or even completely obscuring the amide I band of a peptide”, so it must be removed before infrared secondary-structure determination [8]. The counter-ion review places the strong band near 1700 per centimetre with two further characteristic bands at 1147 and 1200 per centimetre, usable as markers during exchange [1].

Mass spectrometry is the second. Because LC-MS additives must be volatile, trifluoroacetate “is not recommended for use in LC-MS, due to the relatively high ion suppression and lowering of sensitivity”; the usual fixes are reducing TFA from 0.05% to 0.01%, substituting another perfluorinated acid, or balancing a mixture of acetic acid with low TFA [1].

Counter-ion mass and net peptide content

The arithmetic is simple and frequently ignored. Each positive charge on the peptide needs one counter-ion, so the mass penalty scales with the counter-ion’s molecular weight. Trifluoroacetate at 114.02 g/mol [11] is roughly 1.9 times the mass of acetate derived from acetic acid at 60.05 g/mol [12] and roughly 3.1 times the mass of chloride from hydrogen chloride at 36.46 g/mol [13]. For a peptide with several basic residues, converting a trifluoroacetate salt to an acetate therefore raises the peptide fraction of the powder without touching the chromatographic purity figure.

A worked illustration, using arithmetic rather than a real specification: a peptide of molecular weight 3,000 g/mol with three basic sites fully loaded would carry 3 x 114.02 = 342 g/mol of trifluoroacetate, making the peptide about 89.8% of the salt’s mass before any water. The same peptide as a fully loaded acetate would carry 3 x 60.05 = 180 g/mol, about 94.3% peptide. Add 6% water and the measurable peptide content drops roughly to 84% and 89% respectively. The purity by HPLC would be identical in both cases.

This is why EMA separates these numbers in the specification. Its expected analytical content for a synthetic peptide active substance includes assay or content “by LC, elemental analysis, amino acid analysis, nitrogen analysis by Kjeldahl, or qNMR”, plus “counter-ion identity and content, e.g. acetic acid, if relevant” and “residual ion content (TFA)” as a separate test, alongside water content, residual solvents and elemental impurities [2]. The footnote to that list states the reason: “the type of counter ion can affect the biological and physicochemical properties of the peptide and related final formulations”, so “the type of counter ion should be defined, and the amount of counter ions should be controlled in the active substance specification with a justified upper limit” [2].

Two further EMA points change how a certificate should be read. Assay limits determined by liquid chromatography “are expressed in terms of the counter-ion free, anhydrous substance, unless otherwise justified” [2], so an assay result near 100% does not mean the powder is nearly all peptide. And where correction factors are applied at dispensing “based on assay, purity, moisture content, residual solvent content, and/or salt content of active substance”, those factors have to be described in the dossier [2]. For finished products, “the strength of the finished product should be defined with respect to the mass of peptide base (not including salt or counter-ion)” [2]. Our guide to reading a peptide COA works through where these lines appear on a real certificate.

How counter-ions are exchanged

Method	How it works	Reported performance	Limits
Preparative RP-HPLC with a different modifier	Run the final purification with the desired acid as the ion-pairing additive	On lanreotide, gave partial to almost complete exchange to an ion from an acid weaker than TFA, such as acetic acid [7]	Low efficiency; limited choice of compatible ions; HCl is unsuitable because it corrodes stainless-steel pumps, detectors and valves [1]
Ion-exchange resin	Resin bearing quaternary ammonium groups is loaded with the desired anion, then used as a slurry or as a packed column	Described as very universal with very high exchange rates; a carbonate-loaded variant destroys TFA as carbon dioxide while capturing the anion [1]. On lanreotide it gave partial to almost complete exchange [7]	Requires a dedicated step and resin conditioning
Repeated lyophilization from dilute HCl	Dissolve in dilute hydrochloric acid and freeze-dry, several times, then freeze-dry from water to remove excess HCl	Reported efficiency up to about 98% after several repetitions [1]	Time-consuming; incomplete; only works towards acids stronger than TFA, so acetate is unreachable; can hydrolyse peptide bonds [1]
Deprotonation and reprotonation	Take the amino groups through a basic solution, then reprotonate with the chosen acid	Permits complete removal of trifluoroacetate [7]	Exposes the peptide to basic conditions
HCl-saturated organic solvent	Dissolve in acetonitrile or tert-butanol saturated with HCl	Reported as highly efficient after a single repetition with a much shorter operation time, and no degradation observed to date [1]	Newer method, less widely applied

The hydrochloric acid route needs a concentration limit, not just a procedure. In work on indolicidin, hydrochloric acid above 10 mM in unbuffered solutions and above 50 mM in buffered solutions “may modify the peptide structure and reduce its thermal stability”, and 2 to 10 mM was adequate to remove essentially all TFA impurities without modifying the secondary structure [8]. That finding directly contradicts the then-common practice of lyophilizing from 0.1 M HCl [8].

At manufacturing scale the exchange is built into the process rather than bolted on. The ACS analysis notes that “a final ion exchange step is often required after the last purification step to ensure the peptide is associated with the right counterion before going to the final isolation step” [10]. How that fits the rest of downstream processing is covered in our guide to peptide purification.

The three methods evaluated side by side on lanreotide, by 19F NMR, 1H NMR and attenuated total reflectance infrared spectroscopy, were all judged “easy to carry out, fast, harmless and reproducible”, and two of them offered the option of exchanging trifluoroacetate for any other counter-ion [7].

How counter-ions are measured

Technique	What it gives	Notes
Ion chromatography	Identity and content of anions such as TFA, chloride, acetate and sulfonates	”The technique of first choice for counter-ion determination”: relatively inexpensive, sensitive, quantitative and qualitative, with conductivity detection and a suppressor to cut mobile-phase background. Detection limits 10-7 to 10-9 mol/L [1]
19F NMR	Trifluoroacetate identity and content	Characteristic singlet at about minus 75 ppm; applied in a high-throughput format for drug discovery compounds [1] [9]
1H NMR	Organic counter-ions such as acetate	Cannot detect inorganic anions such as chloride, bromide or sulfonate [1]
Capillary electrophoresis	Chloride, acetate, sulfonate and trifluoroacetate	Reported limits of detection and quantification of 0.07 and 0.29 micromol/mL, with low sample and reagent consumption, but higher detection limits and lower precision than ion chromatography [1] [9]
Infrared spectroscopy	Monitors TFA removal	Bands at about 1700, 1200 and 1147 per centimetre [1]
HPLC with UV at 220 nm, or mixed-mode C18 with weak anion exchange	Acetate content alongside the peptide	Recommended approaches for acetate determination; a mixed-mode column gives faster and more precise acetate results [1]
LC-MS/MS with post-column ammonia infusion	Counter-ion and peptide in one run	Ionises acetate for mass detection while polarity switching allows MS/MS of the peptide; useful during development and manufacture [1]

The counter-ion review notes that under both the United States Pharmacopeia and the European Pharmacopoeia, acetate anions in peptide drugs “are regarded as impurities and their levels should be measured before clinical use” [1]. The quantification case was put concisely in a drug-discovery context: it is “imperative to determine the TFA content in order to ascertain the correct formula weight and when required, to ensure that the TFA has been completely exchanged for another counterion” [9].

A practical checklist for research material

1. Ask which salt form you are buying. If no one says, and the peptide was made by Fmoc SPPS and purified by reversed-phase HPLC, assume trifluoroacetate [1].
2. Ask for the counter-ion content, not just the identity. A named salt form without a percentage does not let you calculate how much peptide is in the vial [2].
3. Ask for net peptide content. Purity and peptide fraction are different numbers, and the difference is counter-ion, water and residual solvent [6] [2].
4. For cell work above the nanomolar range, consider exchanging the salt. The osteoblast study recommends conversion to hydrochloride or a biologically equivalent salt before assessing biological effects [3].
5. For infrared structural work, exchange first and keep the acid dilute. 2 to 10 mM HCl removed essentially all TFA without structural change in one study [8].
6. Keep the salt form constant across a study. The encephalomyelitis comparison shows that changing it can move an in vivo readout even when incidence and severity do not change [6].
7. Record it in your methods. Reporting a concentration without the salt form and peptide content leaves the actual exposure undefined [6].

How Winhycare Pharma handles counter-ions

Winhycare Pharma supplies research peptides as research-use-only material, at purity of at least 99% as stated in our product brochure, with QC documentation, and offers custom peptide synthesis, including defined salt form where a project requires it. Semaglutide, tirzepatide, retatrutide, cagrilintide and BPC-157 are also supplied as API to licensed pharmaceutical manufacturers through our peptide API hub; US-DMF and CTD Module 3 support is available for semaglutide only. To ask about a salt form or a counter-ion specification, use the research peptide enquiry form.

For laboratory research use only. Not for human or veterinary use.